{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:06Z","timestamp":1786991466289,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA045745"],"award-info":[{"award-number":["DA045745"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA045848"],"award-info":[{"award-number":["DA045848"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM125507"],"award-info":[{"award-number":["P20GM125507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["H79TI083343"],"award-info":[{"award-number":["H79TI083343"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014913","name":"American Academy of Addiction Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.japh.2022.08.017","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T03:14:05Z","timestamp":1661310845000},"page":"252-260.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas G.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-8716","authenticated-orcid":false,"given":"Alysson E.","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paria","family":"Sanaty Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2022.08.017_bib1","article-title":"Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) Series 63","year":"2021","journal-title":"Substance Abuse and Mental Health Services Administration"},{"issue":"4","key":"10.1016\/j.japh.2022.08.017_bib4","first-page":"e4","article-title":"Opioid policy changes during the COVID-19 pandemic - and beyond","volume":"14","author":"Davis","year":"2020","journal-title":"J\u00a0Addict Med"},{"issue":"2S","key":"10.1016\/j.japh.2022.08.017_bib5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.japh.2022.08.017_bib6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/add.15314","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA","volume":"116","author":"Hill","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2022.08.017_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.08.017_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.08.017_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.japh.2022.08.017_bib10","first-page":"272","article-title":"DEA disconnect leads to buprenorphine bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.japh.2022.08.017_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.08.017_bib12","article-title":"Rural community pharmacist willingness to dispense Suboxone - a secret shopper investigation in South-Central Appalachia","volume":"4","author":"Trull","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"key":"10.1016\/j.japh.2022.08.017_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u2018Red Flags\u2019 and \u2018Red Tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2","key":"10.1016\/j.japh.2022.08.017_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36687","article-title":"Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007\u20132018","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.japh.2022.08.017_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10826084.2019.1670210","article-title":"Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study","volume":"55","author":"Ventricelli","year":"2020","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.japh.2022.08.017_bib17","unstructured":"21 CFR 1306:04(a)."},{"key":"10.1016\/j.japh.2022.08.017_bib18","unstructured":"Raymond N. Pharmacy chains including CVS helped fuel opioid epidemic, U.S. jury finds. Reuters websitehttps:\/\/www.reuters.com\/legal\/litigation\/cvs-other-pharmacy-chains-found-liable-their-first-trial-over-us-opioid-epidemic-2021-11-23\/. Accessed September 13, 2022."},{"key":"10.1016\/j.japh.2022.08.017_bib19","unstructured":"Pattani A. DEA takes aggressive stance toward pharmacies trying to dispense addiction medicine. Available at: https:\/\/www.npr.org\/sections\/health-shots\/2021\/11\/08\/1053579556\/dea-suboxone-subutex-pharmacies-addiction. Accessed September 13, 2022."},{"key":"10.1016\/j.japh.2022.08.017_bib20","unstructured":"Drug Enforcement Administration. Pharmacist\u2019s manual: an informational outline of the controlled substances act:(EO-DEA154)_Pharmacist_Manual.pdf (DEA DC. 046). Available at: https:\/\/www.deadiversion.usdoj.gov\/GDP\/. Accessed September 13, 2022."},{"issue":"8","key":"10.1016\/j.japh.2022.08.017_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn\u2019t enough \u2013 pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3S","key":"10.1016\/j.japh.2022.08.017_bib22","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.japh.2020.01.001","article-title":"Indiana community pharmacist preceptors\u2019 knowledge and perceptions of medication-assisted treatment","volume":"60","author":"Davenport","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.08.017_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.japh.2021.09.012","article-title":"Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction","volume":"62","author":"DiPaula","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2022.08.017_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/08897077.2021.1900988","article-title":"Pharmacists\u2019 stigma toward patients engaged in opioid misuse: when \u201csocial distance\u201d does not mean disease prevention","volume":"42","author":"Werremeyer","year":"2021","journal-title":"Subst Abus"},{"key":"10.1016\/j.japh.2022.08.017_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.08.017_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102722","article-title":"Unintentional drug overdose: is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?","volume":"79","author":"Carlson","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"10","key":"10.1016\/j.japh.2022.08.017_bib27","doi-asserted-by":"crossref","DOI":"10.5688\/ajpe8001","article-title":"Opioid-related education provided by continuing education divisions at US pharmacy schools","volume":"84","author":"Renfro","year":"2020","journal-title":"Am J Pharm Educ"},{"issue":"1","key":"10.1016\/j.japh.2022.08.017_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.japh.2019.09.007","article-title":"Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas","volume":"60","author":"Evoy","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.08.017_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/08897077.2021.2010162","article-title":"Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies","volume":"43","author":"Green","year":"2022","journal-title":"Subst Abus"},{"key":"10.1016\/j.japh.2022.08.017_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103321","article-title":"Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City","volume":"97","author":"Marotta","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2022.08.017_bib31","unstructured":"American Association of Colleges of Pharmacy 2019 final report of the National Pharmacist Workforce Study. Available at: https:\/\/www.aacp.org\/article\/2019-national-pharmacist-workforce-study. Accessed September 13, 2022."}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122002874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122002874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:28Z","timestamp":1761544288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122002874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1544319122002874"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.08.017","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}